Back

Prospective validation of the ARC HBR trade off model in the all comer PIONEER IV trial

2 September 2024 (09:00 - 09:50)
Organised by: Logo
Congress Presentation Part of: All things percutaneous coronary intervention: a potpourri of percutaneous coronary intervention-related topics Outcome ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Tsungying Tsai

University of Galway, Galway (Ireland)

9 More presentations in this session

Presentation thumbnail
Examining prognostic scores for short-term major adverse cardiovascular events prediction following primary PCI: a comparative analysis
Doctor U. Safdar (Karachi, PK)
Abstract Slides Video
Presentation thumbnail
Both fibrosis-4 index and fibrosis-5 index can predict the prognosis of patients after percutaneous coronary intervention
Doctor T. Gu (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Very short-term effects of single dose of proprotein convertase subtilisin kexin 9 inhibitor therapy before percutaneous coronary intervention
Doctor T. Kataoka (Fukui, JP)
Abstract Slides Video
Presentation thumbnail
Optimizing elective high-risk PCI with ECMO support: the value of completely percutaneous use of VA-ECMO
Mr A. Griffioen (Nijmegen, NL)
Abstract Slides Video
Presentation thumbnail
Impact of moderate to severe anemia on clinical outcomes in patients with atrial fibrillation and coronary artery disease requiring percutaneous coronary intervention
Miss K. Abe (Chiba, JP)
Abstract Slides Video

Access the full session

Session thumbnail
All things percutaneous coronary intervention: a potpourri of percutaneous coronary intervention-related topics

The Event

Event poster

ESC Congress 2024

2 September 2024 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Parsimonious versus extensive score: can we simplify bleeding risk stratification after percutaneous coronary intervention without losing specificity?
thumbnail
Congress Presentation
How useful are risk scores in determining bleeding risk and antithrombotic therapy duration after primary PCI?
thumbnail
Congress Presentation
Assessing bleeding and ischaemic risk: which tools and for whom?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources